Literature DB >> 11936739

Factors affecting patient compliance with anti-tuberculosis chemotherapy using the directly observed treatment, short-course strategy (DOTS).

S J O'Boyle1, J J Power, M Y Ibrahim, J P Watson.   

Abstract

SETTING: Kota Kinabalu and surrounding communities in Sabah, Malaysia.
OBJECTIVES: To establish factors affecting compliance of patients with anti-tuberculosis chemotherapy, their knowledge of the disease, and views on improving the DOTS strategy.
DESIGN: Interviews with compliant patients attending clinics for DOTS treatment and with non-compliant patients in their homes, in August and September 2000.
RESULTS: A total of 63 compliant and 23 non-compliant patients were interviewed. For non-compliant patients, reaching the treatment centre entailed greater cost (P < 0.005) and travel time (P < 0.005) compared to compliant patients. Cost of transport was the reason most frequently given for non-attendance. Non-compliant patients were more likely to have completed secondary education (P < 0.05), and to be working (P < 0.01). More non-compliant patients had family members who had had the disease (P < 0.01). There was no difference between the groups for overall tuberculosis knowledge scores; however, non-compliant patients were more likely to think that treatment could be stopped once they were symptom free (P < 0.01). Most patients (73%) felt that the DOTS system could be improved by provision of more information about tuberculosis.
CONCLUSION: Compliance with DOTS in the Kota Kinabalu area is affected by travel expenses, time spent travelling to treatment centres, and having family members who have had the disease. Patients would like more information on tuberculosis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11936739

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN: 1027-3719            Impact factor:   2.373


  26 in total

Review 1.  Antiretroviral therapy in Africa.

Authors:  Warren Stevens; Steve Kaye; Tumani Corrah
Journal:  BMJ       Date:  2004-01-31

2.  Effectiveness of a community-based observation of anti-tuberculosis treatment in Bangalore City, India, 2010-2011.

Authors:  S K Tripathy; P Kumar; K D Sagili; D A Enarson
Journal:  Public Health Action       Date:  2013-09-21

3.  Sputum Collection and Disposal Perceptions and Practices Among Pulmonary Tuberculosis Patients from Northern India.

Authors:  Abhishek Singh; Vipin Goyal; Shewtank Goel
Journal:  J Clin Diagn Res       Date:  2016-12-01

4.  Facility and patient barriers in the implementation of isoniazid preventive therapy for people living with HIV attending Care and Treatment Centers, Songea Municipality, Tanzania.

Authors:  Festo Faustine Komba; Gasto Frumence
Journal:  Pan Afr Med J       Date:  2021-02-22

5.  Determinants of poor adherence to anti-tuberculosis treatment in mumbai, India.

Authors:  Suparna Bagchi; Guirish Ambe; Nalini Sathiakumar
Journal:  Int J Prev Med       Date:  2010

6.  Noncompliance to DOTS: How it can be Decreased.

Authors:  Chhaya Mittal; Sc Gupta
Journal:  Indian J Community Med       Date:  2011-01

7.  Determinants of tuberculosis treatment default in Morocco: results from a national cohort study.

Authors:  Nabil Tachfouti; Katia Slama; Mohamed Berraho; Samira Elfakir; Mohammed Chakib Benjelloun; Karima El Rhazi; Chakib Nejjari
Journal:  Pan Afr Med J       Date:  2013-03-28

8.  Barriers and enablers in the management of tuberculosis treatment in Addis Ababa, Ethiopia: a qualitative study.

Authors:  Mette Sagbakken; Jan C Frich; Gunnar Bjune
Journal:  BMC Public Health       Date:  2008-01-11       Impact factor: 3.295

9.  The impact of smoking on adherence to treatment for latent tuberculosis infection.

Authors:  Mélanie Lavigne; Isabelle Rocher; Colin Steensma; Paul Brassard
Journal:  BMC Public Health       Date:  2006-03-14       Impact factor: 3.295

10.  Default from tuberculosis treatment in Tashkent, Uzbekistan; who are these defaulters and why do they default?

Authors:  Epco Hasker; Maksad Khodjikhanov; Shakhnoz Usarova; Umid Asamidinov; Umida Yuldashova; Marieke J van der Werf; Gulnoz Uzakova; Jaap Veen
Journal:  BMC Infect Dis       Date:  2008-07-22       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.